Imperfect Dataset Bolsters Halozyme's Biomarker Plan For PEGPH20

While not perfect, the latest Phase II data for the stromal depleting agent PEGPH20 give cause for optimism for hyaluronan as a biomarker in pancreatic cancer and for Halozyme's Phase III strategy.